Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05283356

Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

The optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) to prevent valve thrombosis and reduce thromboembolic complications without significantly increasing the risk of bleeding is not yet fully defined and constitutes an important unmet clinical need. Recently, single antiplatelet therapy (SAPT) with Aspirin has been increasingly adopted to avoid bleeding early after TAVI compared with dual antiplatelet therapy. However, TAVI population is affected by a diversity of chronic pathologies that increase the risk of post-TAVI ischemic complications. Stroke is prevalent, especially peri- and early post-TAVI (<1-8% in the 1st year). Although peri-TAVI myocardial infarction (MI) is rare (1-3%), concomitant coronary artery disease (CAD), diabetes mellitus (DM), and peripheral vascular disease (PVD), is very frequent in the TAVI population, affecting around 30-70% of patients. In patients with CAD, the need to re-access the coronary arteries after TAVI is challenging and can be hampered by the trancatheter valve struts.

This is critical in TAVI patients with an acute coronary syndrome and in younger patients with long-life expectancy after TAVI. The use of a P2Y12 inhibitor provides significant ischemic protection in the in the coronary, cerebral and peripheral vascular territories compare to Aspirin. The use of a P2Y12 inhibitor as antiplatelet treatment can decrease the need for new coronary revascularizations and reduce the incidence of thromboembolic complications after TAVI.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Severe Aortic Valve Stenosis Aortic Valve Disease Aortic Valve Stenosis Cardiovascular Diseases Heart Diseases Heart Valve Diseases Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Replacement (TAVR) Ventricular Outflow Obstruction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital Alvaro Cunqueiro

Vigo, Pontevedra, 36312, Spain

Location status: Recruiting

Location contact

Andrés Iñiguez Romo, MD, PhD

PRINCIPAL_INVESTIGATOR

Pablo Juan Salvadores, Pharma, MPH, PhD

CONTACT

[email protected]

+34986825564 ext. 514564

Victor A Jiménez Díaz, MD, MPH

CONTACT

[email protected]

+34986825564 ext. 514564

Victor A Jiménez Díaz, MD, MPH

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of informed consent prior to any study specific procedures.
  • Adult patients (more than 18 years) with ability to understand and accept the participation in the clinical trial.
  • Patients with degenerative symptomatic severe aortic stenosis (AS) accepted for TAVI with any of the commercial approved TAVI devices after evaluation of the Heart Team of each center,and with at least one of the following comorbidities:
  • Diabetes Mellitus, the current WHO diagnostic criteria for diabetes should be maintained - fasting plasma glucose ≥ 7.0mmol/l (126 mg/dl) or 2-h plasma glucose ≥ 11.1mmol/l (200mg/dl), or under treatment with an oral hypoglycemic or insulin.
  • Prior coronary artery disease (STEMI, NSTEMI, stable angina, or others) documented by invasive or non-invasive ischemia screening tests or imaging study.
  • Prior peripheral arterial disease documented by invasive or non-invasive ischemia screening tests or imaging study.
  • Successful TAVI performed by any vascular access.
  • Patients who are not participating in any other clinical trial or research study (registries allowed).

Exclusion criteria

  • Patients under chronic oral anticoagulation for any specific pathology.
  • Patients that cannot undergo a regimen of single antiplatelet therapy after TAVI.
  • History of overt major bleeding or intracranial hemorrhage.
  • Active pathological bleeding.
  • History of ischemic stroke within the last 30 days prior TAVI.
  • Patients with documented severe hepatic insufficiency.
  • Known pregnancy, breast-feeding, or intend to become pregnant during the study period.
  • Concomitant oral or intravenous therapy with potent inhibitors of cytochrome P450 3A (CYP3A) that cannot be suspended during the study.
  • Patients randomized in another clinical trial with an investigational product or device over the past 30 days.
  • Patients who cannot attend follow-up visits scheduled in the study.
  • History of allergic reactions or intolerance to Ticagrelor or Aspirin or any of the excipients.

Treatment and study plan

Ticagrelor 60mg

Drug

Ticagrelor 60mg BID after TAVI

Primary outcomes

  1. Safety and efficacy of Ticagrelor vs Aspirin in the incidence of NACE at 12 months after TAVI.

    Time frame: 12 months

    NACE is a composite of: all-cause mortality, transient ischemic attack (TIA) or stroke, myocardial infarction, progressive angina leading to emergency evaluation,rehospitalization or new coronary angiography, valve thrombosis, claudication, acute limb ischemia leading to hospitalization, any bleeding.

Secondary outcomes

  1. Efficacy endpoint: Subclinical valve thrombosis

    Time frame: 3 and 12 months

    Detected by hypoattenuated leaflet thickening (HALT) and reduced leaflet motion(RLM) at 3 and 12 months after TAVI assessed by 4-dimensional computed tomography (4D-CT) imaging.

    HALT: Hypoattenuating thickening in typically meniscal configuration on one or more leaflets, with or without RLM. The extent of HALT should be described per leaflet, using a 4-tier grading scale in regard to leaflet involvement along the curvilinear contour, assuming maximum involvement at the base of the leaflet:

    ≤25% (limited to the base) >25% and ≤50% >50% and ≤75% >75% Inconclusive for HALT: imaging with insufficient image quality or presence of artifact RLM: The extent of RLM should be described per leaflet, using a 4-tier grading scale None: no reduction in leaflet excursion <50% reduction in leaflet excursion

    ≥50% reduction in leaflet excursion Immobile: immobile leaflet Inconclusive for RLM: imaging with insufficient image quality or presence of artefact

  2. Safety endpoint: Major bleeding

    Time frame: 12 months

    Major bleeding (type 2, 3 and 5) at 12 months after TAVI according BARC (Bleeding Academic Research Consortium)

  3. Patient-oriented composite endpoints

    Time frame: 12 months

    Patient-oriented composite endpoints (POCE) at 12 months after TAVI (POCE is a composite of all-cause mortality,TIA/stroke, myocardial infarction, progressive angina leading to emergency evaluation, rehospitalization or new coronary angiography).

Study contacts

Contact information is provided by the study sponsor or research team.

Pablo Juan-Salvadores, Pharma, MPH, PhD

CONTACT

[email protected]

+34986825564

Victor A Jiménez Díaz, MD, MPH

CONTACT

[email protected]

+34986825564

Sponsors and collaborators

Lead sponsor

Fundacin Biomedica Galicia Sur

Other

Registry information

Official study title

Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial

Acronym: REAC-TAVI2

Important dates

Study start
2022
Primary completion
2027
Study completion
2028
First posted
Mar 16, 2022
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.